The Galaxy BioMill, developed and designed by BIOLASE in conjunction with imes-icore GmbH in Germany, is a CAD/CAM system for scanning, designing, milling and finishing crowns, inlays, and veneers in the dental office in a single appointment. Also termed "chair-side" milling, the market is currently estimated to have reached 15% market penetration in the U.S. and, according to independent research, is one of the fastest growing segments in the dental market. The Galaxy BioMill System will utilize 3Shape Corporation's Trios fast and highly accurate intra-oral scanner to capture high resolution three-dimensional ("3-D") digital images of the teeth and crown-preparation site, which are then processed through a CAD/CAM software program to design the dental restoration. The design is then transferred to the Galaxy BioMill to mill the crown using the latest in aesthetically pleasing, biological compatible, and long-lasting tooth colored materials.
Federico Pignatelli, Chairman and CEO of BIOLASE, explained, "We believe that the Galaxy BioMill is the final key step in the completion of our Total Technology Solution. We can now offer a complete portfolio of unique and standard-of-care changing hard- and soft-tissue dental lasers, 2-D and 3-D digital radiography, and the best-in-class CAD/CAM products. With the addition of the Galaxy BioMill, we can provide a one-stop-shop for dentists for all major high-tech dental capital equipment investments. With this innovative approach, we will allow dentists to obtain training, service, and support of multiple high-tech units from one source only, instead of multiple sources.
"Imes-icore is a world leader in milling technology and the BioMill component of the Galaxy System features unmatched accuracy and has the flexibility to process virtually all CAD/CAM milling block materials up to 60mm for size in both wet and dry milling. This flexibility is further enhanced by features normally only found in high-end mills used by dental laboratories, such as a 6 position tool changer with digital tool management, 4 axis processing, and a high precision 360 degrees A-axis processing station which provides all-important vibration-free stability.
"With its open architecture, the Galaxy BioMill with 3Shape CAD/CAM software can also provide a cost-effective milling solution for the many Cadent iTero, 3M Lava, and, of course, 3Shape Trios intra-oral scanner users who recognize the significant return on investment that it offers and clinical benefits of adding chair-side milling to their practices. The Galaxy BioMill System will compete with market leaders such as the Cerec CAD/CAM System, from Sirona, and the E4D System, distributed by Henry Schein," concluded Pignatelli.
Cristoph Stark, Managing Director of Imes-Icore GmbH, said, "We are very excited about this strong alliance and partnership with BIOLASE and 3Shape. 3Shape and imes-icore were one of the first partners to cooperate in creating full dental CAD/CAM solutions on a high level, and both parties have vast experience and interest for developing additional chairside functionality. We look forward to expanding our technology into dental practices with BIOLASE as a very powerful partner in North America."
3Shape's General Manager, North American Operations, Henrik Vestermark, also commented, "3Shape is pleased to play a key part in the joint development of the Galaxy BioMill System and welcomes the significant opportunity for increased penetration of the important North American market that BIOLASE provides us. We have worked closely with imes-icore for many years and believe that the move to combining digital scanning with CAD/CAM restorations creates a paradigm shift in dental care with benefits for dentists and patients being proven every day."
Imes-icore GmbH is a wholly-owned subsidiary of the isel-Group and a world leader in milling equipment based in Eiterfield, Germany. The "imes" stands for "integrated mechanics, electronics and software" and the "icore" represents "integrated dental solutions." Imes-icore's mission is to develop highly flexible dental production systems through global alliances with increasing efficiency, quality of software, and using innovative materials. For further information regarding imes-icore, please refer to www.imes-icore.de.
3Shape is a Danish company specializing in the development and marketing of 3-D scanners and CAD/CAM software solutions designed for the creation, processing, analysis and management of high-quality 3-D data for application in complex manufacturing processes. 3Shape envisions the Age of "Full Digital Dentistry," and its more than 140 developers provide superior innovation power toward reaching this goal. 3Shape's flexible solutions empower dental professionals through automation of real workflows, and its systems are applied in thousands of labs in more than 90 countries worldwide, putting 3Shape technologies at the peak of the market in relation to units produced per day by dental technicians.
With Trios, 3Shape now brings its vast expertise and innovation power directly to dentists. 3Shape boosts its first-line distributor support network with a second-line support force of over 30 in-house experts placed in 5 support and service centers strategically located around the globe. 3Shape is a privately-held company headquartered in Copenhagen, with the market's largest team dedicated to scanner and software development for the dental segment, based in Denmark and Ukraine, production facilities in Poland, and Business Development & Support Offices at several locations in Europe, in North and South America, and in Asia. For further information regarding 3Shape, please refer to www.3shapedental.com. Visit us on www.facebook.com/3shape, or view our mobile site on m.3shapedental.com.
About BIOLASE, Inc.
BIOLASE, Inc. is a biomedical company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment and CAD/CAM intraoral scanners; products that are focused on technologies that advance the practice of dentistry and medicine. The Company's proprietary laser products incorporate approximately 300 patented and patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold more than 23,900 lasers. Other laser products under development address ophthalmology and other medical and consumer markets.
For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc and YouTube at www.youtube.com/biolasevideos.
BIOLASE®, WaterLase®, and Galaxy BioMill are registered trademarks or trademarks of BIOLASE, Inc.
Trios® is a registered trademark of 3Shape A/S LLC and NewTom is a trademark of QR S.r.l. Corporation, a wholly-owned subsidiary of Cefla Capital Services, S.p.A.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives, product introductions and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current perspective of existing trends and information and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors affecting BIOLASE's business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.